or
Remember me
Back
** Canadian pharmaceutical company's shares down as much as 12.2 at pct at C$20.02; lowest in almost 28 months
** U.S.-listed shares down 9.9 pct at $15.41
** RBC Capital Markets cuts PT on U.S. stock to $33 from $40; Median PT $40.14
** "We anticipate that the UK's vote to leave the E.U. has, not surprisingly, likely complicated the ongoing strategic review process," RBC Capital Markets analysts write in a note
** Brokerage also cites company's risks related to integration, acquisitions, clinical trial failures, reliance on third parties for manufacturing and significant debt load among other things
** Up to Monday's close, company's Toronto-listed shares had fallen 60 pct this year
A daily snapshot of everything from market open to close.